| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | Bleselumab Basic information |
| Product Name: | Bleselumab | | Synonyms: | Bleselumab;Research Grade Bleselumab (DHD68902);Research Grade Bleselumab;Bleselumab (anti-CD40) | | CAS: | 1453067-91-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bleselumab Structure]() |
| | Bleselumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Bleselumab Usage And Synthesis |
| Uses | Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection[1]. | | in vivo | Bleselumab (0.1-10mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys[2].
Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys[3].
Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus (HY-13756) shows a longer median survival time (MST) than monotherapy[3].
| Animal Model: | Cynomolgus monkeys[2].
| | Dosage: | 0.1, 1 and 10mg/kg | | Administration: | Intravenous injection (i.v.) | | Result: | Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner. |
| | References | [1] Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171. DOI:10.1111/ajt.15591
[2] Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9. DOI:10.1111/ajt.12678
[3] Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76. DOI:10.1097/TP.0000000000000236 |
| | Bleselumab Preparation Products And Raw materials |
|